MSB 2.76% $1.76 mesoblast limited

MSB trading, page-9

  1. 3,443 Posts.
    lightbulb Created with Sketch. 1638
    With a FDA phase 3 trial succeeding, there is a partner there 100% if they wanted it.

    Financially it would mean giving up future cash flows, so SI will need to figure out the best path forward for shareholders. Do another cap raise (at a reasonable price) before partnering CHF, lower back pain... or partner pediatric aGVHD resolve the short term cash problem but give away future cash flows.

    This is a long term investment, irrational decisions now can have a significant detrimental effect to the long term value of MSB.

    More importantly though, the technology is being validated in FDA phase 3 clinical trials. MSB’s MSC technology is no longer a “dream”, it is now becoming reality. 2018 milestone year.

    NIH sponsored 2b CHF LVAD trial up next.
    Last edited by stockrock: 26/02/18
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $944.5M
Open High Low Value Volume
$1.83 $1.85 $1.75 $4.373M 2.459M

Buyers (Bids)

No. Vol. Price($)
1 6243 $1.76

Sellers (Offers)

Price($) Vol. No.
$1.77 1629 1
View Market Depth
Last trade - 16.10pm 18/10/2019 (20 minute delay) ?
-0.050 ( 3.22 %)
Open High Low Volume
$1.83 $1.85 $1.75 215717
Last updated 15.59pm 18/10/2019 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.